Patents Assigned to Justus Liebig Universität Giessen
-
Patent number: 11680256Abstract: A bacterial strain comprising one or more vectors encoding a) one or more enzymes to produce one or more terpene precursors; and b) a fungal terpene synthase (FTPS). The present invention also relates to a method of producing a terpenoid comprising a) culturing the bacterial strain described herein in an expression medium; and b) isolating the terpenoid from said expression medium.Type: GrantFiled: September 2, 2019Date of Patent: June 20, 2023Assignees: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Congqiang Zhang, Xixian Chen, Ruehl Martin, Heng-Phon Too
-
Patent number: 11116221Abstract: The technology provided herein relates to methods of multi-species insect pest control by incorporating an inhibitor against the structural sheath protein (SHP) into the body of an agricultural target pest, and to pest control agents to be used in the method and to transgenic crop, greenhouse and ornamental plants.Type: GrantFiled: May 28, 2014Date of Patent: September 14, 2021Assignees: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V., JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Torsten Will, Andreas Vilcinskas, Rainer Fischer
-
Patent number: 10964519Abstract: The invention relates to an apparatus for mass-spectrometric analysis and three-dimensional imaging of the surface of a sample, comprising at least one energy source for desorbing and/or ionizing atoms from the surface of a sample, a displacement stage, and a light source. Further, it comprises an interface in order to be able to interchange data with a mass spectrometer such that measurement data can be transmitted from a mass spectrometer to the evaluation unit via the interface such that the chemical composition of the measurement point can be determined by the evaluation unit. The surface of a sample can be captured in three dimensions and the topography of this surface can be determined by the evaluation unit.Type: GrantFiled: October 6, 2017Date of Patent: March 30, 2021Assignee: JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Bernhard Spengler, Mario Kompauer
-
Patent number: 10501803Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.Type: GrantFiled: May 21, 2014Date of Patent: December 10, 2019Assignees: MAX-PLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., JUSTUS-LIEBIG-UNIVERSITÄT GIESSENInventors: Guillermo Barreto, Aditi Mehta, Indrabahadur Singh, Marten Szibor, Rajkumar Savai, Werner Seeger, Thomas Braun, Andreas Günther, Marcus Krüger
-
Publication number: 20160135466Abstract: The technology provided herein relates to methods of multi-species insect pest control by incorporating an inhibitor against the structural sheath protein (SHP) into the body of an agricultural target pest, and to pest control agents to be used in the method and to transgenic crop, greenhouse and ornamental plants.Type: ApplicationFiled: May 28, 2014Publication date: May 19, 2016Applicants: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Torsten Will, Andreas Vilcinskas, Rainer Fischer
-
Patent number: 9309147Abstract: The invention relates to a coating of glass with thermochromic vanadium dioxide. The coloration of the vanadium dioxide is shifted from bronze to neutral (colorless) by a doping with alkaline earth metals, for example Ca, Sr and Br. The thermochromic effect is maintained at the same time.Type: GrantFiled: June 19, 2013Date of Patent: April 12, 2016Assignee: JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Bruno K. Meyer, Angelika Polity, Marc Konstantin Dietrich
-
Patent number: 9150638Abstract: The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.Type: GrantFiled: April 1, 2011Date of Patent: October 6, 2015Assignee: Justus-Liebig-Universität GiessenInventors: Ewa Jablonska, Klaus Preissner, Malgorzata Wygrecka
-
Patent number: 8912332Abstract: The present invention describes tripodal catechol derivatives with a flexible basic framework for the functionalization of surfaces, and methods for their production and use. The central atom of the flexible framework is hereby a tertiary aliphatic carbon atom. The remaining fourth bridgehead position is easily suitable to be further functionalized via so-called click reactions, e.g. with biomolecules, dyes, radiomarkers, polyethylene glycol or active agents.Type: GrantFiled: September 7, 2011Date of Patent: December 16, 2014Assignee: Justus-Liebig-Universitaet GiessenInventors: Wolfgang Maison, Faiza Khalil, Elisa Franzmann
-
Patent number: 8829233Abstract: The present invention describes tripodal bisphosphonate derivatives with a flexible basic framework for the functionalization of surfaces, and methods for their production and use. The central atom of the flexible framework is hereby a tertiary aliphatic carbon atom. A fourth remaining position of the flexible framework is suitable to be optionally functionalized by so-called click reactions, for example with biomolecules, polyethylene glycol or active agents.Type: GrantFiled: September 7, 2011Date of Patent: September 9, 2014Assignee: Justus-Liebig-Universitaet GiessenInventors: Wolfgang Maison, Elisa Franzmann, Faiza Khalil
-
Patent number: 8765712Abstract: The present invention concerns an agent for prevention and treatment of pityriasis. The agent according to the present invention comprises at least one transaminase inhibitor effectively inhibiting the transamination process which is of pathogenetic relevance for the disease, prevents a recurrence of the disease and which protects the human skin flora. Upon release into the environment, no resistances are induced in other fungi.Type: GrantFiled: January 14, 2010Date of Patent: July 1, 2014Assignee: Justus-Liebig-Universitaet GiessenInventor: Peter Mayser
-
Publication number: 20140127311Abstract: The present invention provides biocompatible nano-polymer particles which are composed of a biocompatible polymer, a stabilizer and an active agent for the treatment of pulmonary hypertension or erectile dysfunction and which can be used to produce a pharmaceutical preparation for the treatment of pulmonary hypertension or erectile dysfunction. Biocompatible nano-polymer particles of this invention have a diameter ranging from 10 nm to 10 ?m auf, a stabilizing layer thickness between 0 and 50 nm, contain between 0 and 50% of an active agent for the treatment of pulmonary hypertension or erectile dysfunction, are nebulizable and continuously release the active agent over a period of up to 48 hours. Biocompatible nano-polymer particles of this invention can be synthesized for example using the emulsion technique known to the expert with subsequent solvent evaporation or via spray drying.Type: ApplicationFiled: May 23, 2012Publication date: May 8, 2014Applicant: JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Moritz Beck-Broichsitter, Thomas Schmehl, Tobias Gessler, Thomas Kissel
-
Patent number: 8716539Abstract: Dinitroxylated diamantanes are suitable for being reacted with nucleophiles to form the corresponding disubstituted diamantanes. Surprisingly, at least dinitroxylated or hydroxylated diamantanes are rearranged in the presence of a strong acid and at least 4,9-nitroxylated or hydroxylated diamantanes are created. On this basis, 4,9-substituted diamantanes are able to be produced in a targeted manner by reaction with further nucleophiles.Type: GrantFiled: December 4, 2006Date of Patent: May 6, 2014Assignee: Justus-Liebig-Universitaet GiessenInventors: Peter R. Schreiner, Andrey A. Fokin
-
Publication number: 20140099379Abstract: The present invention provides stabilizers for the coating of biocompatible nano- and microparticles which prevent aggregation of the particles during preparation, storage as well as before and after nebulization and which are suitable to be utilized for the manufacture of a pharmaceutical preparation for pulmonary application. Biocompatible nano- and microparticles of this invention have a stabilizer layer thickness ranging from 1 to 200 nm and contain an active substance. Said biocompatible nano- and microparticles of this invention can be synthesized for example using the emulsion method known to the expert with subsequent coating by mixing of uncoated particles with the stabilizer, by chemical vapor deposition, by spraying or by covalent attachment.Type: ApplicationFiled: May 23, 2012Publication date: April 10, 2014Applicant: JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Moritz Beck-Broichsitter, Tobias Gessler, Thomas Schmehl
-
Publication number: 20130217916Abstract: The present invention describes tripodal catechol derivatives with an adamantyl basic framework for the functionalisation of surfaces, and methods for their production and use. A fourth remaining position of the adamantane skeleton is suitable to be optionally functionalised by so-called click reactions, for example with biomolecules, polyethylene glycol or active agents.Type: ApplicationFiled: September 7, 2011Publication date: August 22, 2013Applicant: JÜSTUS-LIEBIG-UNIVERSITÄT GIESSENInventors: Wolfgang Maison, Elisa Franzmann, Faiza Khalil
-
Publication number: 20130115638Abstract: The present invention concerns a procedure and a device to determine the concentration of protamine-1 and protamine-2 and the ratio between protamine-1 and protamine-2 as protamine/protein ratio in a questionable sample from an individual to be examined in order to assess the fertility of the sperm in vitro. This assessment is of great importance for the prognosis of the success of an artificial insemination of an egg in vitro. The test strip comprises a sperm pretest to determine the sperm concentration and a protamine rapid test to determine the concentrations of protamine-1 and protamine-2 and the ratio between protamine-1 and protamine-2 as protamine/protein ratio.Type: ApplicationFiled: May 17, 2011Publication date: May 9, 2013Applicant: JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Klaus Steger, Agnieszka Paradowska, Birte Bärmann
-
Publication number: 20130095108Abstract: The present invention provides methods for treating interstitial lung diseases, comprising administering to an individual an effective amount of an inhibitor of coagulation factor XII. The invention further provides uses and pharmaceutical kits for that treatment.Type: ApplicationFiled: April 1, 2011Publication date: April 18, 2013Applicant: JUSTUS-LIEBIG-UNIVERSITÄT GIESSENInventors: Ewa Jablonska, Klaus Preissner, Malgorzata Wygrecka
-
Patent number: 8377343Abstract: The invention relates to a novel optical function layer and its production, the function layer imparting to materials coated with it protection against uv radiation while transmitting electromagnetic radiation of larger wavelengths. The function layer of the invention and the manufacturing method of the invention offer advantages over the state of the art by allowing very accurate and precise adjustability in the uv range of the relatively sharp absorption constant.Type: GrantFiled: September 7, 2004Date of Patent: February 19, 2013Assignee: Justus-Liebig-Universität GiessenInventors: Bruno K. Meyer, Baker Farangis, Detlev Hofmann, Thorsten Krämer, Angelika Polity
-
Publication number: 20120171658Abstract: The present invention relates to a device and a procedure for the withdrawal, manufacture, storage and transportation of blood products in the widest sense, in particular a closed blood removal, processing and storages system, as well as a system suitable for the administration of medicinal products which are obtained from blood or blood products, and a corresponding procedure for the legally conformant and GMP-compliant preparation, manufacture, storage and transportation of blood products or blood components or blood constituents or blood preparations (within the meaning of the Medical Products Act AMG). The present invention in particular allows the manufacture, storage, transportation and administration of completely aliquoted autologous serum eye drops for direct application to the patient or other drugs manufactured from blood or blood products without the need for clean room laboratories.Type: ApplicationFiled: May 27, 2010Publication date: July 5, 2012Applicant: JUSTUS-LIEBIG-UNIVERSITÄT GIESSENInventors: Gregor Bein, Holger Hackstein, Joachim Misterek
-
Patent number: 8124588Abstract: The present invention relates to recombinant chimeric proteins comprising a surfactant protein precursor N-terminally fused to a plasminogen activator or comprising a mature surfactant protein N-terminally or C-terminally fused to a plasminogen activator. The invention is also directed to the corresponding nucleic acid molecules encoding such fusion proteins as well as to a method for their production. The invention further refers to a pharmaceutical composition comprising such a fusion protein and to pharmacological uses of an inventive fusion protein for the prevention and/or treatment of inflammatory and interstitial lung diseases.Type: GrantFiled: December 18, 2003Date of Patent: February 28, 2012Assignee: Justus Liebig Universität GiessenInventors: Werner Seeger, Andreas Günther, Clemens Ruppert, Philipp Markart, Viktor Magdolen, Timothy E. Weaver
-
Publication number: 20110308605Abstract: Provided is a fluorescent diamondoid material which when energized, either by an electric field or by high energy radiation, emits light. The light emitted is generally in the visible range. The diamondoid material can be fine tuned by internal or external doping. The fluorescent materials comprised of diamondoids, have applications in several fields. One application is in solar cells where these materials can be used to improve the overall efficiency of the device. A second application is in indoor lighting where the materials can be used to efficiently produce white light. This can be done by either using the material as a fluorescent medium for a UV light source, in an electroluminescence device, or by using the material as part of an organic light emitting diode (OLED).Type: ApplicationFiled: January 30, 2009Publication date: December 22, 2011Applicants: Justus-Liebig-Universitaet Giessen, Leland J. Stanford Junior UnivesityInventors: Zhi Liu, Will Clay, Michael A. Kelly, Nicholas A. Melosh, Zhi-Xun Shen, Andrey A. Fokin, Peter R. Schreiner